<p><img src="https://imageproxy.pbkrs.com/https://images.pexels.com/photos/5849595/pexels-photo-5849595.jpeg/query-YXV0bz1jb21wcmVzcyZjcz10aW55c3JnYiZkcHI9MSZ3PTUwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.pexels.com/photos/5849595/pexels-photo-5849595.jpeg/query-YXV0bz1jb21wcmVzcyZjcz10aW55c3JnYiZkcHI9MSZ3PTUwMA"/></p>
<p><em>圖片來源：Pexels</em></p>
<p>雖然 “便宜股票” 沒有確切的定義，因為這取決於個人偏好，但通常指的是每股交易價格在 5 到 10 美元之間的上市公司。便宜股票涵蓋多個行業，提供了多樣化投資組合的眾多機會。</p>
<h3><strong>為什麼要考慮投資便宜股票？</strong></h3>
<p>便宜股票可以為耐心的投資者提供令人興奮的增長機會，前提是他們知道該尋找什麼。它們還可以讓投資者接觸到尖端技術、醫學、人工智能以及其他尚未取得突破但即將顛覆其行業的公司。</p>
<p>在評估便宜股票時，有幾個事項需要考慮：</p>
<ul>
<li>投資於擁有成功管理團隊的便宜股票，該團隊有扭轉公司局面的歷史。</li>
<li>研究並瞭解行業，以及便宜股票如何通過其產品或服務產生顯著影響。</li>
<li>仔細分析資產負債表，深入研究多個季度的財務報告，以確保便宜股票的債務較低，收入增長，並且有充足的現金儲備。</li>
<li>始終為便宜股票保持一個單獨的投資組合。</li>
</ul>
<h3><strong>便宜股票的缺點是什麼？</strong></h3>
<p>投資者必須理解，便宜股票以低廉價格交易是有原因的，在投入資金之前，他們必須知道價格為何如此。可能存在財務問題、運營風險、法律麻煩以及其他投資者應當注意的問題。風險較高，流動性較低導致波動性仍然較大。</p>
<p>以下是當前值得考慮的便宜股票的簡短列表：</p>
<ul>
<li>瑞穗金融集團 (MFG)</li>
<li>土耳其電信 (TKC)</li>
<li>CytomX 治療 (CTMX)</li>
<li>Solid Power (SLDP)</li>
<li>Epsium 企業 (EPSM)</li>
<li>BigBear.ai 控股公司 (BBAI)</li>
<li>Magnitude International (MAGH)</li>
<li>Compass (COMP)</li>
<li>Navitas 半導體公司 (NVTS)</li>
<li>美國銻業公司 (UAMY)</li>
</ul>
<h3><strong>我之前推薦的最佳便宜股票更新</strong></h3>
<p>在我們之前的文章中，我強調了瑞穗金融集團和土耳其電信的上行潛力。</p>
<ul>
<li>瑞穗金融集團 - 在 6.48 美元到 6.75 美元之間建立了多頭頭寸。瑞穗最初下跌，然後上漲近 7%。此後股價回落至接近我的入場水平，我將繼續持有我的多頭頭寸。</li>
<li>土耳其電信 - 在 5.35 美元到 5.62 美元之間建立了多頭頭寸。股價上漲超過 8% 後，隨後又回落。該股票最近在我的入場區間內交易，我正在持有這一交易。</li>
</ul>
<h3><strong>CytomX 治療的基本面分析</strong></h3>
<p>CytomX 治療是一家臨牀階段的生物製藥公司，專注於通過更強效、毒性更低的抗癌藥物來革新癌症治療，主要產品為 Probody 治療。</p>
<p>那麼，在 CytomX 治療的收益未達預期後，我為什麼仍然看好它？</p>
<p>收入為 600 萬美元，每股虧損 0.09 美元，未達到預期。儘管收入下降令人擔憂，但我對其管線持樂觀態度，CX-801 在晚期黑色素瘤患者中的第一階段結果令人鼓舞，CX-2051 在晚期結直腸癌中的初步臨牀結果也很強勁。CX-2051 在其他晚期患者中也顯示出潛力，包括肝轉移和 KRAS 突變患者。</p>
<p><img src="https://imageproxy.pbkrs.com/https://talkmarkets.com/contributor/julianna-linder/user_content/ckimages/orig_5_638995144213401683.webp?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://talkmarkets.com/contributor/julianna-linder/user_content/ckimages/orig_5_638995144213401683.webp"/></p>
<p><em>CytomX 治療基本面分析快照</em></p>
<p>CytomX 治療的市盈率為 12.82，使其成為一隻便宜的股票。相比之下，標準普爾 500 指數的市盈率為 29.87。分析師對 CytomX 治療的平均目標價為 7.07 美元。這表明具有良好的上行潛力和可接受的下行風險。</p>
<h3><strong>CytomX 治療的技術分析</strong></h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.dailyforex.com/files/ctmx.webp?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.dailyforex.com/files/ctmx.webp"/></p>
<p><em>(點擊圖片放大)</em></p>
<p><em>CytomX 價格圖表</em></p>
<p>該股票的 D1 圖表顯示 CytomX 的價格在其下降的 38.2% 和 50.0% 斐波那契回撤扇形之間的價格走勢。它還顯示該股票處於其水平支撐區間內。</p>
<p>此外，牛熊力量指標呈現看漲趨勢，且趨勢線向上。</p>
<h3><strong>我對 CytomX 治療的看法</strong></h3>
<p>我在 CytomX 治療股票的價格區間為 3.49 美元到 3.93 美元之間建立了多頭頭寸。儘管價格低於 5.00 美元，但它具有巨大的上行潛力，現金餘額健康，沒有立即的運營問題，並且管線前景良好。</p>
<h3><strong>Solid Power 基本面分析</strong></h3>
<p>Solid Power 開發下一代全固態電池技術。除了開發全固態電池單元技術外，它還向其他活躍於固態領域的公司銷售硫化物固體電解質。</p>
<p>那麼，在 Solid Power 的收益報告後，我為什麼仍然看好它？</p>
<p>截至目前的收入為 1810 萬美元，比去年增加 240 萬美元。運營費用在減少，其資本狀況保持良好，這得益於其市場發行和政府合同。在 Solid Power 與三星 SDI 和寶馬達成有前景的合同後，我轉為看好，確認了其全固態電池單元技術在工業應用中的信心。</p>
<p><img src="https://imageproxy.pbkrs.com/https://talkmarkets.com/contributor/julianna-linder/user_content/ckimages/orig_5_638995144882942547.webp?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://talkmarkets.com/contributor/julianna-linder/user_content/ckimages/orig_5_638995144882942547.webp"/></p>
<p><em>Solid Power 基本面分析快照</em></p>
<p>Solid Power 股票的市盈率數據不可用。該股票的平均分析師目標價為 7.00 美元。這表明具有良好的上行潛力和降低的下行風險。</p>
<h3><strong>Solid Power 技術分析</strong></h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.dailyforex.com/files/sldp.webp?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.dailyforex.com/files/sldp.webp"/></p>
<p><em>(點擊圖片放大)</em></p>
<p><em>Solid Power 價格圖表</em></p>
<p>D1 圖表顯示 Solid Power 的價格走勢低於其上升的斐波那契回撤扇形，同時也顯示該股票接近其水平支撐區。</p>
<p>此外，牛熊力量指標呈現看跌趨勢，但一條上升趨勢線已經開始形成。</p>
<h3><strong>我對 Solid Power 的看法</strong></h3>
<p>我將在 Solid Power 股票的價格區間為 4.32 美元至 4.77 美元之間建立多頭頭寸。儘管 Solid Power 的運營指標令人擔憂，但其業務正在朝着正確的方向發展。其資本狀況依然優秀，與三星 SDI 和寶馬的近期合作預計將在未來幾個季度提供顯著的看漲催化劑。</p>
<hr/>
<p><em>更多來自此作者的文章：</em></p>
<p>Fastenal 股票信號：您應該為您的投資組合加固嗎？</p>
<p>值得購買的最佳核能股票</p>
<p>現在值得購買的最佳黃金股票</p>

瑞穗金融集團

CytomX治療

<p>這篇文章討論了投資於便宜股票的潛力，這些股票通常每股價格在 5 到 10 美元之間，涵蓋多個行業。文章強調了此類投資的增長機會和風險。文章提供了一份值得考慮的便宜股票的簡短名單，包括瑞穗金融集團、土耳其電信公司、CytomX 治療和 Solid Power。它對 CytomX 治療和 Solid Power 進行了基本面和技術分析，強調了它們有前景的產品線和財務狀況</p>

<p><img src="https://imageproxy.pbkrs.com/https://images.pexels.com/photos/5849595/pexels-photo-5849595.jpeg/query-YXV0bz1jb21wcmVzcyZjcz10aW55c3JnYiZkcHI9MSZ3PTUwMA" alt="" original-src="https://images.pexels.com/photos/5849595/pexels-photo-5849595.jpeg?auto=compress&amp;cs=tinysrgb&amp;dpr=1&amp;w=500"/></p>
<p><em>Image Source: Pexels</em></p>
<div class="lb-trans"><p><em>圖片來源：Pexels</em></p>
</div><p>While there is no exact definition of “cheap stocks,” as it depends on individual preferences, they typically refer to listed companies that trade between $5 and $10 per share. Cheap stocks are available across various sectors and offer numerous opportunities to diversify portfolios.</p>
<div class="lb-trans"><p>雖然 “便宜股票” 沒有確切的定義，因為這取決於個人偏好，但通常指的是每股交易價格在 5 到 10 美元之間的上市公司。便宜股票涵蓋多個行業，提供了多樣化投資組合的眾多機會。</p>
</div><h3><strong>Why Should You Consider Investing in Cheap Stocks?</strong></h3>
<div class="lb-trans"><h3><strong>為什麼要考慮投資便宜股票？</strong></h3>
</div><p>Cheap stocks can offer exciting growth opportunities for patient investors who know what to look for. They can also provide exposure to cutting-edge technology, medicine, AI, and other companies that have not yet achieved a breakthrough but are on the verge of disrupting their industries.</p>
<div class="lb-trans"><p>便宜股票可以為耐心的投資者提供令人興奮的增長機會，前提是他們知道該尋找什麼。它們還可以讓投資者接觸到尖端技術、醫學、人工智能以及其他尚未取得突破但即將顛覆其行業的公司。</p>
</div><p>Here are a few things to consider when evaluating cheap stocks:</p>
<div class="lb-trans"><p>在評估便宜股票時，有幾個事項需要考慮：</p>
</div><ul>
<li>Invest in cheap stocks with a proven management team that has a history of turning around companies.</li>
<li>Research and understand the industry and how a cheap stock can make a notable impact with their product or service.</li>
<li>Analyze the balance sheet carefully and dig through several quarters of financial reports to ensure the cheap stock is low on debt, has growing revenues, and plenty of cash reserves.</li>
<li>Always keep a separate portfolio for cheap stocks.</li>
</ul>
<div class="lb-trans"><ul>
<li>投資於擁有成功管理團隊的便宜股票，該團隊有扭轉公司局面的歷史。</li>
<li>研究並瞭解行業，以及便宜股票如何通過其產品或服務產生顯著影響。</li>
<li>仔細分析資產負債表，深入研究多個季度的財務報告，以確保便宜股票的債務較低，收入增長，並且有充足的現金儲備。</li>
<li>始終為便宜股票保持一個單獨的投資組合。</li>
</ul>
</div><h3><strong>What are the Downsides of Cheap Stocks?</strong></h3>
<div class="lb-trans"><h3><strong>便宜股票的缺點是什麼？</strong></h3>
</div><p>Investors must understand that cheap stocks trade at bargain prices for a reason, and before they commit capital, they must know why the price is where it is. There could be financial issues, operational risks, legal troubles, and other problems that investors should be aware of. The risk is higher, and volatility remains elevated due to less liquidity.</p>
<div class="lb-trans"><p>投資者必須理解，便宜股票以低廉價格交易是有原因的，在投入資金之前，他們必須知道價格為何如此。可能存在財務問題、運營風險、法律麻煩以及其他投資者應當注意的問題。風險較高，流動性較低導致波動性仍然較大。</p>
</div><p>Here is a shortlist of cheap stocks currently worth considering:</p>
<div class="lb-trans"><p>以下是當前值得考慮的便宜股票的簡短列表：</p>
</div><ul>
<li>Mizuho Financial Group (MFG)</li>
<li>Turkcell Iletisim Hizmetleri (TKC)</li>
<li>CytomX Therapeutics (CTMX)</li>
<li>Solid Power (SLDP)</li>
<li>Epsium Enterprise (EPSM)</li>
<li>BigBear.ai Holdings, Inc. (BBAI)</li>
<li>Magnitude International (MAGH)</li>
<li>Compass (COMP)</li>
<li>Navitas Semiconductor Corporation (NVTS)</li>
<li>United States Antimony Corporation (UAMY)</li>
</ul>
<div class="lb-trans"><ul>
<li>瑞穗金融集團 (MFG)</li>
<li>土耳其電信 (TKC)</li>
<li>CytomX 治療 (CTMX)</li>
<li>Solid Power (SLDP)</li>
<li>Epsium 企業 (EPSM)</li>
<li>BigBear.ai 控股公司 (BBAI)</li>
<li>Magnitude International (MAGH)</li>
<li>Compass (COMP)</li>
<li>Navitas 半導體公司 (NVTS)</li>
<li>美國銻業公司 (UAMY)</li>
</ul>
</div><h3><strong>Update on My Previous List of Best Cheap Stocks to Buy Now</strong></h3>
<div class="lb-trans"><h3><strong>我之前推薦的最佳便宜股票更新</strong></h3>
</div><p>In our previous installment, I highlighted the upside potential of Mizuho Financial Group and Turkcell Iletisim Hizmetleri.</p>
<div class="lb-trans"><p>在我們之前的文章中，我強調了瑞穗金融集團和土耳其電信的上行潛力。</p>
</div><ul>
<li>Mizuho Financial Group - A long position was taken in the stock between $6.48 and $6.75. Mizuho initially moved lower before advancing almost 7%. It has since retreated close to my entry level, and I will continue holding my long position.</li>
<li>Turkcell Iletisim Hizmetleri - A long position was taken in the stock between $5.35 and $5.62. After rising by over 8%, shares rallied and then dropped again. The stock has recently been trading inside my entry zone, and I am holding this trade.</li>
</ul>
<div class="lb-trans"><ul>
<li>瑞穗金融集團 - 在 6.48 美元到 6.75 美元之間建立了多頭頭寸。瑞穗最初下跌，然後上漲近 7%。此後股價回落至接近我的入場水平，我將繼續持有我的多頭頭寸。</li>
<li>土耳其電信 - 在 5.35 美元到 5.62 美元之間建立了多頭頭寸。股價上漲超過 8% 後，隨後又回落。該股票最近在我的入場區間內交易，我正在持有這一交易。</li>
</ul>
</div><h3><strong>CytomX Therapeutics Fundamental Analysis</strong></h3>
<div class="lb-trans"><h3><strong>CytomX 治療的基本面分析</strong></h3>
</div><p>CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on revolutionizing cancer treatments with more potent, less toxic anti-cancer medications, led by its Probody therapeutics product.</p>
<div class="lb-trans"><p>CytomX 治療是一家臨牀階段的生物製藥公司，專注於通過更強效、毒性更低的抗癌藥物來革新癌症治療，主要產品為 Probody 治療。</p>
</div><p>So, why am I bullish on CytomX Therapeutics after its earnings miss?</p>
<div class="lb-trans"><p>那麼，在 CytomX 治療的收益未達預期後，我為什麼仍然看好它？</p>
</div><p>Revenues of $6.0 million and an earnings per share loss of $0.09 per share missed estimates. While the drop in revenues was a concern, I am bullish about its pipeline, with promising Phase 1 results for CX-801 in advanced melanoma patients and robust initial clinical results for CX-2051 in late-line colorectal cancer. CX 2051 also shows potential in other late-stage patients, including those with liver metastases and KRAS mutations.</p>
<div class="lb-trans"><p>收入為 600 萬美元，每股虧損 0.09 美元，未達到預期。儘管收入下降令人擔憂，但我對其管線持樂觀態度，CX-801 在晚期黑色素瘤患者中的第一階段結果令人鼓舞，CX-2051 在晚期結直腸癌中的初步臨牀結果也很強勁。CX-2051 在其他晚期患者中也顯示出潛力，包括肝轉移和 KRAS 突變患者。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://talkmarkets.com/contributor/julianna-linder/user_content/ckimages/orig_5_638995144213401683.webp" alt="" original-src="https://talkmarkets.com/contributor/julianna-linder/user_content/ckimages/orig_5_638995144213401683.webp"/></p>
<p><em>CytomX Therapeutics Fundamental Analysis Snapshot</em></p>
<div class="lb-trans"><p><em>CytomX 治療基本面分析快照</em></p>
</div><p>The price-to-earnings (P/E) ratio of 12.82 makes CytomX Therapeutics an inexpensive stock. By comparison, the P/E ratio for the S&amp;P 500 Index is 29.87. The average analyst price target for CytomX Therapeutics is $7.07. This suggests excellent upside potential with acceptable downside risks.</p>
<div class="lb-trans"><p>CytomX 治療的市盈率為 12.82，使其成為一隻便宜的股票。相比之下，標準普爾 500 指數的市盈率為 29.87。分析師對 CytomX 治療的平均目標價為 7.07 美元。這表明具有良好的上行潛力和可接受的下行風險。</p>
</div><h3><strong>CytomX Therapeutics Technical Analysis</strong></h3>
<div class="lb-trans"><h3><strong>CytomX 治療的技術分析</strong></h3>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.dailyforex.com/files/ctmx.webp" alt="" original-src="https://www.dailyforex.com/files/ctmx.webp"/></p>
<p><em>(Click on image to enlarge)</em></p>
<div class="lb-trans"><p><em>(點擊圖片放大)</em></p>
</div><p><em>CytomX price chart</em></p>
<div class="lb-trans"><p><em>CytomX 價格圖表</em></p>
</div><p>The stock D1 chart shows CytomX's price action between its descending 38.2% and 50.0% Fibonacci Retracement Fan. It also shows the stock inside its horizontal support zone.</p>
<div class="lb-trans"><p>該股票的 D1 圖表顯示 CytomX 的價格在其下降的 38.2% 和 50.0% 斐波那契回撤扇形之間的價格走勢。它還顯示該股票處於其水平支撐區間內。</p>
</div><p>Additionally, the Bull Bear Power Indicator is bullish with an ascending trendline.</p>
<div class="lb-trans"><p>此外，牛熊力量指標呈現看漲趨勢，且趨勢線向上。</p>
</div><h3><strong>My Call on CytomX Therapeutics</strong></h3>
<div class="lb-trans"><h3><strong>我對 CytomX 治療的看法</strong></h3>
</div><p>I am taking a long position in CytomX Therapeutics stock between $3.49 and $3.93. While the price is below $5.00, it has tremendous upside potential, with a healthy cash balance, no immediate operational concerns, and a promising pipeline.</p>
<div class="lb-trans"><p>我在 CytomX 治療股票的價格區間為 3.49 美元到 3.93 美元之間建立了多頭頭寸。儘管價格低於 5.00 美元，但它具有巨大的上行潛力，現金餘額健康，沒有立即的運營問題，並且管線前景良好。</p>
</div><h3><strong>Solid Power Fundamental Analysis</strong></h3>
<div class="lb-trans"><h3><strong>Solid Power 基本面分析</strong></h3>
</div><p>Solid Power develops next-generation all-solid-state battery technology. Besides developing all-solid-state battery cell technology, it also sells sulfide solid electrolytes to other companies active in the solid-state sectors.</p>
<div class="lb-trans"><p>Solid Power 開發下一代全固態電池技術。除了開發全固態電池單元技術外，它還向其他活躍於固態領域的公司銷售硫化物固體電解質。</p>
</div><p>So, why am I bullish on Solid Power after its earnings report?</p>
<div class="lb-trans"><p>那麼，在 Solid Power 的收益報告後，我為什麼仍然看好它？</p>
</div><p>Year-to-date revenues came in at $18.1 million, up $2.4 million versus last year. Operating expenses are decreasing, and its capital position remains excellent, thanks to its at-the-market offering and government contracts. I turned bullish after Solid Power secured promising contracts with Samsung SDI and BMW, confirming confidence in its industrial application for its all-solid-state battery cell technology.</p>
<div class="lb-trans"><p>截至目前的收入為 1810 萬美元，比去年增加 240 萬美元。運營費用在減少，其資本狀況保持良好，這得益於其市場發行和政府合同。在 Solid Power 與三星 SDI 和寶馬達成有前景的合同後，我轉為看好，確認了其全固態電池單元技術在工業應用中的信心。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://talkmarkets.com/contributor/julianna-linder/user_content/ckimages/orig_5_638995144882942547.webp" alt="" original-src="https://talkmarkets.com/contributor/julianna-linder/user_content/ckimages/orig_5_638995144882942547.webp"/></p>
<p><em>Solid Power Fundamental Analysis Snapshot</em></p>
<div class="lb-trans"><p><em>Solid Power 基本面分析快照</em></p>
</div><p>The price-to-earnings (P/E) data for Solid Power stock is unavailable. The average analyst price target for the stock is $7.00. This suggests excellent upside potential with decreasing downside risks.</p>
<div class="lb-trans"><p>Solid Power 股票的市盈率數據不可用。該股票的平均分析師目標價為 7.00 美元。這表明具有良好的上行潛力和降低的下行風險。</p>
</div><h3><strong>Solid Power Technical Analysis</strong></h3>
<div class="lb-trans"><h3><strong>Solid Power 技術分析</strong></h3>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.dailyforex.com/files/sldp.webp" alt="" original-src="https://www.dailyforex.com/files/sldp.webp"/></p>
<p><em>(Click on image to enlarge)</em></p>
<div class="lb-trans"><p><em>(點擊圖片放大)</em></p>
</div><p><em>Solid Power Price Chart</em></p>
<div class="lb-trans"><p><em>Solid Power 價格圖表</em></p>
</div><p>The stock D1 chart shows Solid Power's price action trading below its ascending Fibonacci Retracement Fan. It also shows the stock approaching its horizontal support zone.</p>
<div class="lb-trans"><p>D1 圖表顯示 Solid Power 的價格走勢低於其上升的斐波那契回撤扇形，同時也顯示該股票接近其水平支撐區。</p>
</div><p>Additionally, the Bull Bear Power Indicator is bearish, but an ascending trendline has begun to form.</p>
<div class="lb-trans"><p>此外，牛熊力量指標呈現看跌趨勢，但一條上升趨勢線已經開始形成。</p>
</div><h3><strong>My Call on Solid Power</strong></h3>
<div class="lb-trans"><h3><strong>我對 Solid Power 的看法</strong></h3>
</div><p>I am taking a long position in Solid Power stock between $4.32 and $4.77. While Solid Power has troubling operational metrics, its business is moving in the right direction. Its capital position remains excellent, and recent partnerships with Samsung SDI and BMW should provide a significant bullish catalyst in the quarters to come.</p>
<div class="lb-trans"><p>我將在 Solid Power 股票的價格區間為 4.32 美元至 4.77 美元之間建立多頭頭寸。儘管 Solid Power 的運營指標令人擔憂，但其業務正在朝着正確的方向發展。其資本狀況依然優秀，與三星 SDI 和寶馬的近期合作預計將在未來幾個季度提供顯著的看漲催化劑。</p>
</div><hr/>
<div class="lb-trans"><hr/>
</div><p><em>More By This Author:</em></p>
<div class="lb-trans"><p><em>更多來自此作者的文章：</em></p>
</div><p>Fastenal Stock Signal: Should You Fasten Your Portfolio?</p>
<div class="lb-trans"><p>Fastenal 股票信號：您應該為您的投資組合加固嗎？</p>
</div><p>The Best Nuclear Energy Stocks To Buy</p>
<div class="lb-trans"><p>值得購買的最佳核能股票</p>
</div><p>The Best Gold Stocks To Buy Now</p>
<div class="lb-trans"><p>現在值得購買的最佳黃金股票</p>
</div>

當前最值得購買的廉價股票